News

Explore the intersection of Taylor Swift's music, relationships, and their impact on mental well-being in today's society.

FDA approves Tonmya, a groundbreaking fibromyalgia treatment, offering hope for pain relief after 15 years without new options.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

What are the cultural implications of President Trump's Kennedy Center Honors selections?

Psychodynamically-informed pharmacotherapy is much more than “prescribing.”

Current crises threaten children's health and mental well-being globally, highlighting the urgent need for action and support from psychiatry and society.

The complexities of Huntington disease can pose challenges for diagnosis. Let's take a look at its neuropsychiatric symptoms and the need for comprehensive treatment strategies.

"Tonight their eyes meet with the spirit of sacred music..."

Discover the complexities of sleep-related eating disorder, its symptoms, triggers, and effective treatments for better sleep health.

Dysphoric milk ejection reflex (D-MER) causes brief emotional distress during breastfeeding, often misdiagnosed as postpartum depression, requiring better awareness and support.

Hurricane Katrina's legacy highlights the urgent need for trauma-informed mental health care in disaster recovery, addressing PTSD and long-term emotional impacts.

PharmaTher's KETARx gains FDA approval, paving the way for innovative ketamine treatments in pain management and mental health disorders.

Effective strategies for managing child agitation focus on individualized care, multidisciplinary support, and proactive interventions to ensure safety and calm.

Researchers uncover how serotonin receptor 5-HT1A influences drug interactions, paving the way for faster, targeted psychiatric treatments.

New executive order targets homeless individuals through institutionalization, raising concerns about stigma and lack of real solutions for vulnerable populations.

Explore the intersection of psychiatry and politics as H. Steven Moffic, MD, reflects on Canadian unity and the challenges facing mental health services today.

Explore the evolution and therapeutic potential of GLP-1, a key incretin in diabetes management and weight loss solutions.

UK study of "active ingredients" in early psychosis intervention is applicable to US programs, according to the codirector of Stanford's INSPIRE Clinic.

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Let's examine the mental health challenges faced by Native Americans and First Nations, highlighting historical trauma and the need for reparative actions.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Let's examine innovative psychiatric approaches to address social conflicts, such as empathy, understanding, and the potential for healing in turbulent times.

Youth with neurodevelopmental disorders face significant suicide risks.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

What are the parallels between train travel and psychiatric care?

We want to emphasize the importance of diversity in mental health care, offering resources to enhance culturally informed practices for all clinicians.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.